Global mRNA Flu Vaccine Market, By Type (Non-replicating mRNA, In Vivo Self-Replicating mRNA, In Vitro Dendritic Cell Non-Replicating mRNA Vaccine), Product Type (mRNA-1010, mRNA-1020, mRNA-1030), Route of Administration (Intravenous, Intramuscular, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
mRNA Flu Vaccine Market Analysis and Size
Rise in the prevalence of influenza, growing healthcare expenditure, advancement in technology, growing government funding, rising initiatives by government and private organisations to spread awareness about the mRNA vaccines are the factors that will expand the global mRNA flu vaccine market. Rise in the research and development activities and ongoing clinical trials will provide beneficial opportunities for the global mRNA flu vaccine market in the forecast period of 2023 to 2030.
Data Bridge Market Research analyses that the global mRNA flu vaccine market which was USD 7.89 billion in 2022, is expected to reach USD 14.76 billion by 2030, and is expected to undergo a CAGR of 9.3% during the forecast period of 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
mRNA Flu Vaccine Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Non-replicating mRNA, In Vivo Self-Replicating mRNA, In Vitro Dendritic Cell Non-Replicating mRNA Vaccine), Product Type (mRNA-1010, mRNA-1020, mRNA-1030), Route of Administration (Intravenous, Intramuscular, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
|
|
Countries Covered
|
U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Moderna, Inc. (U.S.), BioNTech SE (Germany), CureVac AG (Germany), Novavax, Inc. (U.S.), Translate Bio, Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), Arcturus Therapeutics Holdings Inc. (U.S.), eTheRNA immunotherapies (Belgium), Valneva SE (France), Vaxart, Inc. (U.S.), Entos Pharmaceuticals (Canada), Abnova Corporation (Taiwan), Anima Biotech (U.S.), Biontech Pharmaceuticals (China), Sarepta Therapeutics (U.S.), iBio, Inc. (U.S.), Vaccitech (U.K.), Alnylam Pharmaceuticals, Inc. (U.S.), Beam Therapeutics (U.S.), Chardan Healthcare Acquisition 2 Corp (U.S.)
|
|
Market Opportunities
|
|
Market Definition
An mRNA flu vaccine is a type of influenza vaccine that utilizes messenger RNA (mRNA) technology to stimulate an immune response against the influenza virus. Instead of using a weakened or inactivated form of the virus, as traditional flu vaccines often do, mRNA vaccines work by introducing a small piece of synthetic mRNA into the body.
Global mRNA Flu Vaccine Market Dynamics
Drivers
- Pandemic Preparedness and Responsiveness
One of the significant drivers for the mRNA flu vaccine market is the urgent need for pandemic preparedness and rapid response to emerging influenza strains. The mRNA vaccine technology allows for the swift development and deployment of vaccines targeting new and potentially dangerous flu variants. This capability is crucial in mitigating the impact of potential flu pandemics and reducing their spread.
- Enhanced Vaccine Effectiveness
The mRNA flu vaccines have demonstrated the potential for improved vaccine effectiveness compared to traditional flu vaccines. They can induce a stronger and more specific immune response, leading to better protection against a broader range of influenza strains. This enhanced effectiveness is a key driver as healthcare providers and patients seek vaccines that offer higher levels of protection.
- Technological Advancements for Developing the Vaccines
Continuous technological advancements in mRNA vaccine development have propelled the mRNA flu vaccine market. Researchers have gained a deeper understanding of mRNA vaccine platforms, leading to improvements in vaccine stability, production efficiency, and delivery methods. These advancements make mRNA vaccines more accessible and attractive to the healthcare industry.
Opportunities
- Shift Toward Preventive Healthcare
There is a growing global shift toward preventive healthcare, and vaccination plays a pivotal role in disease prevention. As individuals and healthcare systems prioritize preventive measures, the demand for effective and advanced vaccines like mRNA flu vaccines is on the rise.
- Rising Healthcare Expenditure
The overall increase in healthcare expenditure across the globe allows patients to access a wider range of healthcare services, including vaccination. As healthcare budgets expand, there is more room for investment in advanced vaccine technologies like mRNA vaccines.
Restraints/Challenges
- Vaccine Hesitancy and Education
Vaccine hesitancy remains a significant challenge in healthcare. Some individuals may be hesitant to receive mRNA flu vaccines due to concerns about new vaccine technologies, side effects, or misinformation. Overcoming vaccine hesitancy and educating the public about the safety and efficacy of mRNA vaccines is an ongoing challenge.
- Cold Chain Requirements
The mRNA vaccines often require specific storage and transportation conditions, including ultra-cold temperatures. Maintaining the cold chain throughout the distribution process can be logistically challenging, especially in regions with limited infrastructure.
This global mRNA flu vaccine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global mRNA flu vaccine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global mRNA Flu Vaccine Market Scope
The global mRNA flu vaccine market is segmented on the basis of type, product type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
Type
- Non-Replicating mRNA
- In Vivo Self-Replicating mRNA
- In Vitro Dendritic Cell Non-Replicating mRNA Vaccine
Product Type
- mRNA-1010
- mRNA-1020
- mRNA-1030
Route of Administration
- Intravenous
- Intramuscular
- Others
End User
- Clinic
- Hospital
- Others
Global mRNA Flu Vaccine Market Regional Analysis/Insights
The global mRNA flu vaccine market is analysed and market size information is provided by the country, type, product type, route of administration, end-users and distribution channel as referenced above.
The countries covered in the global mRNA flu vaccine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global mRNA flu vaccine market due to the presence of major key players, growing investment for R&D activities, high healthcare expenditure and well-developed healthcare sector in this region.
Asia-Pacific is expected to show a rapid and lucrative growth rate in the global mRNA flu vaccine market during the forecast period of 2023 to 2030 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed Base and New Technology Penetration
The global mRNA flu vaccine market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for the global mRNA flu vaccine market impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on global mRNA flu vaccine market. The data is available for historic period 2015-2020.
Competitive Landscape and Global mRNA Flu Vaccine Market Share Analysis
The global mRNA flu vaccine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global mRNA flu vaccine market.
Some of the major players operating in the global mRNA flu vaccine market are:
- Moderna, Inc. (U.S.)
- BioNTech SE (Germany)
- CureVac AG (Germany)
- Novavax, Inc. (U.S.)
- Translate Bio, Inc. (U.S.)
- Inovio Pharmaceuticals, Inc. (U.S.)
- Arcturus Therapeutics Holdings Inc. (U.S.)
- eTheRNA immunotherapies (Belgium)
- Valneva SE (France)
- Vaxart, Inc. (U.S.)
- Entos Pharmaceuticals (Canada)
- Abnova Corporation (Taiwan)
- Anima Biotech (U.S.)
- Biontech Pharmaceuticals (China)
- Sarepta Therapeutics (U.S.)
- iBio, Inc. (U.S.)
- Vaccitech (U.K.)
- Alnylam Pharmaceuticals, Inc. (U.S.)
- Beam Therapeutics (U.S.)
- Chardan Healthcare Acquisition 2 Corp (U.S.)
SKU-